Jones Day has advised Japan’s Astellas Pharma on its $5.9 billion acquisition of U.S. drugmaker Iveric Bio, which was represented by Skadden, Arps, Slate, Meagher & Flom and Wilmer Cutler Pickering Hale and Dorr.

This is the second-largest cross-border acquisition by a Japanese drugmaker in the past five years, following Takeda Pharmaceutical's $6 billion purchase of Nimbus Therapeutics' psoriasis drug unit that was announced last December, Reuters reported.

This acquisition, the largest for Astellas, is expected to give it access to a range of ophthalmology treatments, Reuters added.

Partner Jonn Beeson led the Jones Day team.


Related Articles

Malaysia’s ASL hires two corporate, finance partners

by Nimitt Dixit |

Malaysian law firm Adnan Sundra & Low (ASL) has expanded its corporate offerings with the addition of M&A partner Liza Uma and banking and finance partner Yong Wee Hoo.

Cleary, DLA advise on $1.1 bln Japan-Sweden pharma deal

Cleary Gottlieb Steen & Hamilton and Swedish law firm Gernandt & Danielsson Advokatbyrå are advising Japan’s Asahi Kasei on its $1.1 billion offer to buy Swedish drugmaker Calliditas Therapeutics, which is being counselled by DLA Piper.

SAM rainmaker Iqbal Khan takes 20-strong M&A group to JSA

by Nimitt Dixit |

Indian law firm J. Sagar Associates has poached a team of around 20 M&A lawyers from Shardul Amarchand Mangaldas & Co led by rainmaker Iqbal Khan. They constitute some of JSA’s most prominent lateral hires in what has already been a frantic year of recruitment to date.